As the managing partner of 5AM Ventures, Dr. Scott Rocklage can be called “an innovator.” Just the title of his business attests to this point. When asked about this name, Scott informed his interviewer that his business is a venture capital firm that becomes involved with companies that are in their earliest stages. In order to acknowledge those early beginnings, he thought it would be a good idea to call his company “5AM Ventures.”
His day to day activities do not follow any particular pattern. Some days, he spends his time looking for the new things that life science can offer the world. Other days, he is needed to contribute to the management of the company. He also needs to take time to prepare for and attend the company’s board meetings and more information click here.
Scott’s time is largely spent with the scientists, executives and physicians who have ideas for new medications and treatments but need someone to help them polish these ideas, and Scott is the one to do this. He helps them develop a solution to the illnesses and medical conditions that do not currently have an adequate answer.
As a venture capitalist in the medical field, Scott is involved in many very interesting topics. For example, his company is in the process of targeting mutations and genotypes that medical professionals will be able to use to treat cancer as it has never been done before and Scott’s lacrosse camp.
Before Scott Rocklage became the managing partner of 5AM Ventures, he spent many years gaining the skills and experience needed to make his company work. He attended the University of California, Berkeley and received a Bachelor of Science in Chemistry. Afterward, he moved on to the Massachusetts Institute of Technology and graduated with a Ph.D. in Chemistry. Currently, more than 30 U.S. patents have Dr. Rocklage’s name on them as an inventor or co-inventor.
Scott has also spent 30 years in healthcare management and is respected for his leadership in several trials. He won approval by the FDA for three drug applications, including Omniscan, Teslascan and Cubicin and placed six drug candidates in clinical trials.
Dr. Rocklage took a turn as a Venture Partner in his company “5AM Ventures” in 2003, and in 2004, he became a Managing Partner. In 2016, he joined EPIRUS Biopharmaceuticals and was also the Acting Chief Officer for the company that year. In addition to that, he became its Director and served as such from 2014 until 2016.
Scott was named as President of Cubist Pharmaceuticals in 1994 and served in that capacity until March of 2001. He was the company’s Founding Chief Executive Officer from 1994 until 2003. Furthermore, he was the President and CEO of Nycomed Salutar beginning in 1990 and ending in 1994. From 1992 until 1994, he was also CEO, Chairman and President of Nycomed Interventional, Inc.
Dr. Rocklage was a part of the Research & Development team at Catalytica and Salutar and was Board Chairman of both Relypsa an Novira. He also served as the Director at Relypsa for 14 years. Additionally, he spent 10 years as Cubist Pharmaceuticals’ Director.
Dr. Rocklage is currently a member on several boards, including Epirus and Pulmatrix. He is Chairman of the Board for Cidara and has been with them since 2013. He became the Chairman of Novira Therapeutics, Inc. in 2012 and is a member of the board for Kinestral and Rennovia, Inc. He also served as Executive Chairman of Semprus BioSciences Corporation, Miikana and Ilyps and learn more about Scott.
Final Words of Wisdom
Dr. Rocklage advises other entrepreneurs to take risks. It is your choice if you want to work for an established company, but you will do much better for yourself if you control your own future.
More visit: http://www.rennovia.com/team/scott-m-rocklage/